Menu
← Oncology Approval Tracker
FDA DECISION ·
Perjeta + Herceptin Hylecta
pertuzumab + trastuzumab and hyaluronidase-oysk · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Added subcutaneous trastuzumab and hyaluronidase-oysk as an option with pertuzumab in its existing HER2-positive settings: qualifying neoadjuvant disease, high-risk early adjuvant disease, and first-line metastatic disease with docetaxel.
LAMPGEN ANALYSIS
Why it matters
Enabled a subcutaneous trastuzumab option while retaining intravenous pertuzumab in labeled combinations.
What research teams should watch
Keep the two product routes distinct and retain HER2 testing and cardiac monitoring.
PRIMARY RECORDS